



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC

Alternative Name

PD-L1, SP142

Methodology

Immunohistochemistry (IHC)

Test Description

The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue on a VENTANA BenchMark ULTRA instrument. Evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity. Primary or metastatic NSCLC tissues may be submitted.

Stain-only (tech-only) testing is available to clients who have completed the test kit manufacturer's online interpretation training.

Clinical Significance

PD-L1 expression in ≥50% tumor cells or ≥10% tumor infiltrating immune cells as determined by this assay in NSCLC tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab). This test is a complementary diagnostic for use of Tecentriq in certain NSCLC cases.

Specimen Requirements

- A formalin-fixed, paraffin-embedded (FFPE) tissue block is preferred specimen type or
- One (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody ordered
- Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
- For PD-L1 SP142 evaluation, tissue submitted must have ≥50 viable tumor cells present.

Storage & Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

New York Approved

Yes

Level of Service

Stain Only, Global

Turnaround Time

Global: 48 hours, Tech-Only (stain only): 24 hours

References

1. TECENTRIQ® [package insert]. South San Francisco, CA: Genentech, Inc.; Revised 7/2018

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 050324